Drug Profile

mbIL 15 TCR T cell therapy - Alaunos Therapeutics

Alternative Names: mbIL-15 TCR-T cell therapy - Alaunos Therapeutics; mbIL-15 TCR-T cells - Alaunos

Latest Information Update: 12 Jan 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator ZIOPHARM Oncology
Developer Alaunos Therapeutics
Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

30 Mar 2022 Alaunos Therapeutics announces intention to submit IND application for mbIL 15 TCR T cell therapy in the second half of 2023
01 Feb 2022 Alaunos Therapeutics files for international patent application for mbIL 15 TCR T cell therapy
26 Jan 2022 ZIOPHARM Oncology is now called Alaunos Therapeutics

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com